LogoCrystal's MCW Coder Hub

92084

39 min read

đŸ©ș CPT Code 92084: Documentation & Billing Guide

Visual field examination, unilateral or bilateral, with interpretation and report

Last Updated: February 2026
Status: 2025 Medicare Fee Schedule Compliant
Specialty Tags: ophthalmology optometry diagnostic visualfield perimetry

Quick Reference Table

ElementDetails
CPT Code92084
Code TypeDiagnostic Procedure - Ophthalmology/Optometry
Procedure TypeVisual field examination, unilateral or bilateral, with interpretation and report; extended examination with spherical isopters and static threshold determination within central 30 degrees, or kinetic determination with multiple isopters
Global PeriodXXX (No global period; diagnostic test only)
Work RVU (2025)0.54
PE RVU (2025, Non-Facility)0.56
PE RVU (2025, Facility)0.19
Malpractice RVU (2025)0.03
Total RVU (2025, Non-Facility)1.13
Total RVU (2025, Facility)0.76
Medicare Payment (Non-Facility)~32.35 CF × GPCI)
Medicare Payment (Facility)~32.35 CF × GPCI)
2025 Conversion Factor$32.35
Estimated Commercial Insurance$200 - 600+
Medicaid Range (State-Dependent)$25 - 150
Procedure Time20-45 minutes per eye
Place of ServiceOffice (11), Outpatient Hospital (22), ASC (24)
Typical SpecialtyOphthalmology, Optometry, Neuro-Ophthalmology

📋SHORT DEFINITION

CPT 92084 describes visual field examination with automated or manual perimetry testing using spherical isopters and static threshold determination within the central 30 degrees, or kinetic determination with multiple isopters, performed unilaterally or bilaterally, with physician interpretation and written report. The test measures visual sensitivity across the entire field of vision to detect peripheral vision loss, visual field defects, and abnormalities indicative of glaucoma, optic nerve disease, retinal disorders, or neurological conditions.

LONG DEFINITION

Overview

CPT 92084 is a comprehensive diagnostic ophthalmologic procedure that uses automated or manual perimetry equipment to systematically test a patient’s visual field sensitivity at multiple locations, creating a detailed topographic map of the visual field. The test detects and quantifies visual field loss, monitors disease progression, and helps establish baseline measurements for future comparison.

Key characteristics:

  • Automated or manual testing: Humphrey Field Analyzer, Octopus, or Goldmann kinetic perimetry

  • Extended examination: Tests the central 30° with at least three isopters (if kinetic) or full threshold testing (if automated)

  • Interpretation and written report: Physician reviews data, compares to age-matched normal values, correlates with clinical findings

  • Per eye or bilateral: Can test one eye or both eyes; unilateral or bilateral designation clarifies billing

  • No radiologic component: Unlike retrograde pyelography or imaging, this is a functional diagnostic test

Clinical Indications

1. Glaucoma Screening and Diagnosis

  • Initial evaluation for suspected glaucoma

  • Establish baseline visual field in newly diagnosed glaucoma

  • Family history of glaucoma with risk factors

  • Elevated intraocular pressure (IOP >21 mmHg)

  • Suspicious optic nerve appearance (cupping, pallor, asymmetry)

  • Most common indication for 92084

2. Glaucoma Monitoring and Progression Analysis

  • Serial visual field testing to detect disease progression

  • Monitor response to glaucoma therapy (medication or surgery)

  • Frequency: Typically every 6-12 months for stable glaucoma; more frequent (3-6 months) for progressive disease

  • Early detection of field loss allows treatment adjustment before significant vision loss

3. Optic Nerve Disease Evaluation

  • Optic neuropathy (various etiologies: ischemic, hereditary, demyelinating, compressive)

  • Papilledema (elevated intracranial pressure; visual field may show enlarged blind spot, depression)

  • Optic nerve compression from tumor, mass, or other structural lesion

  • Visual field pattern helps localize optic nerve pathology

4. Neurological Visual Loss

5. Retinal Disorders

6. Unexplained Vision Loss or Visual Symptoms

  • Patients reporting vision loss, dimness, or visual complaints

  • Visual field testing localizes loss (central vs peripheral, unilateral vs bilateral, homonymous vs hemianopic)

  • Helps differentiate ocular vs neurological etiologies

  • Objective measurement when patient perception unclear

7. Post-Operative Monitoring

  • After refractive surgery (LASIK, PRK, etc.)

  • After cataract surgery to assess visual function

  • After retinal procedures or laser treatments

  • Baseline for medicolegal documentation

8. Blepharoplasty Candidacy Assessment

  • Visual field testing before eyelid surgery to document baseline

  • Upper eyelid ptosis or dermatochalasis reducing superior visual field

  • Confirms visual field deficiency is not from other ocular pathology

  • Medicolegal protection pre-operatively

Procedure Technique

Patient Preparation:

  • NPO status: Generally not required (non-invasive diagnostic test)

  • Visual acuity check: Corrected visual acuity documented (critical for interpreting test validity)

  • Cycloplegic refraction (optional): May be performed before testing; helps optimize focus for perimetry

  • Correction lens: Contact lens or trial frame placed to correct for test distance (typically 33 cm)

  • Pupil assessment: Document pupil size (dilated, naturally dilated, or undilated); affects test sensitivity

  • Anesthesia: None required; topical anesthesia NOT used (would suppress vision)

  • Positioning: Patient positioned at chin rest and forehead rest of perimetry equipment

Equipment:

Automated Perimetry (Most Common for 92084):

  • Humphrey Field Analyzer (HFA): Most common; uses Goldmann III size stimulus

  • Octopus Perimeter: Alternative automated device

  • Test algorithms: SITA Standard, SITA Rapid (faster), Full Threshold (most accurate)

  • Stimulus parameters: White stimulus on gray background; intensity measured in decibels (dB)

  • Fixation monitoring: Real-time eye tracking to verify patient maintains gaze at fixation target

Kinetic Perimetry (Goldmann Manual Perimetry):

  • Goldmann Perimeter: Manual perimetry; examiner moves stimulus from periphery toward center

  • Isopters: Multiple light intensities tested (Roman numerals: I, II, III, IV, V; or sizes/intensities)

  • For 92084: Must plot at least 3 isopters with static determination in central 30°

  • Static determination: Testing specific central locations (not just kinetic tracking)

Operative Steps - Automated Perimetry (Humphrey 30-2 or 24-2, most common for 92084):

  1. Equipment Setup and Calibration:

    • Perimeter calibrated

    • Patient positioned with chin and forehead at rest

    • Appropriate trial lens inserted for refractive error correction

    • Fixation target displayed in center of bowl

  2. Patient Instruction:

    • Patient instructed: “Keep your eye fixed on the center target”

    • “Press the button whenever you see a light, even if very dim”

    • “Press button even if unsure; better to press and be wrong than miss lights”

    • Patient practices with training stimuli

  3. Test Initiation - Initial Screening (Usually Suprathreshold or SITA):

    • Machine presents light stimuli at predetermined locations

    • Stimuli vary in intensity (brightness/decibels)

    • Patient presses button when light perceived

    • Computer tracks fixation; alerts if patient not looking at target

  4. Threshold Testing (Full Threshold Algorithm - Standard for 92084):

    • At each test location, computer narrows stimulus brightness to find threshold (minimum brightness patient perceives)

    • Automated algorithm: Computer uses patient responses to intelligently choose next stimulus intensity

    • Adaptive approach: If patient sees stimulus, next is dimmer (finding lower threshold); if patient misses, next is brighter

    • Result at each point: Threshold value (in dB) representing visual sensitivity at that location

    • Higher dB values = better vision; lower dB values = visual field loss

  5. Test Quality Assessment (CRITICAL for Interpretation):

    • Fixation losses: How often patient’s eye drifted from center target? (<20% generally acceptable)

    • False positives: Did patient press button when no stimulus presented? (>33% suggests unreliability or trigger-happy response)

    • False negatives: Did patient miss high-intensity stimuli at locations known to be seeing? (>33% suggests fatigue, inattention, or inability to maintain task)

    • Reliability index: Test marked as “Reliable,” “Borderline,” or “Unreliable”

  6. Data Analysis:

    • Sensitivity map (threshold values): Numeric values displayed at each test point

    • Gray scale plot: Visual representation; darker areas = lower sensitivity (field loss)

    • Total Deviation (TD) plot: Compares patient’s thresholds to age-matched normal database; shows areas worse than normal

    • Pattern Deviation (PD) plot: Removes generalized depression; highlights focal defects

    • Mean Deviation (MD): Overall depression of visual field (negative values = worse than normal)

    • Pattern Standard Deviation (PSD): Amount of focal irregularity in field (higher PSD = more focal defects)

    • Glaucoma Hemifield Test (GHT): Proprietary glaucoma-detection algorithm (categories: “Within Normal Limits,” “Borderline,” “Outside Normal Limits”)

    • Visual Field Index (VFI): Percent of visual field remaining (useful for monitoring progression)

  7. Comparison with Prior Tests (If Available - CRITICAL):

    • Visual field results compared to previous tests

    • Progression analysis: Is field stable, progressing (worsening), or improving?

    • Trend analysis: Trend software (HFA Trend Analysis) may show graphical progression over multiple years

    • Critical for glaucoma management decisions

  8. Test Completion:

    • Patient thanked and advised of completion

    • Patient may be drowsy or fatigued; brief rest offered

    • Physician reviews raw data and automated analysis

Operative Steps - Goldmann Kinetic Perimetry (For 92084, Requires Multiple Isopters + Central 30° Static):

  1. Setup:

    • Patient positioned at Goldmann perimeter

    • Appropriate trial lens correcting for test distance

    • Fixation target in center of bowl

  2. Kinetic Testing (Multiple Isopters):

    • Examiner sets stimulus intensity (Roman numeral: I, II, III, IV, V representing brightness levels)

    • Examiner moves small dot stimulus from periphery (non-seeing area) toward center (seeing area)

    • Patient signals when stimulus becomes visible

    • Examiner marks this boundary point (isopter)

    • Process repeated at multiple meridians (radial lines from center)

  3. Static Testing in Central 30°:

    • After kinetic isopters plotted, static testing performed in central 30°

    • Examiner presents stationary stimulus at various central locations

    • Patient indicates if visible; thresholds determined similar to automated testing

    • Identifies central scotomas, blind spots, areas of depression

  4. For 92084 Goldmann Requirement:

    • At least 3 isopters must be plotted (e.g., III/4mm white, II/4mm white, I/4mm white, or different colors)

    • Static determination within central 30° (not just peripheral isopter tracking)

    • Test provides both kinetic (peripheral isopters) and static (central sensitivity) information

Post-Procedure:

  • Patient dismissed (no recovery period needed; non-invasive)

  • Physician reviews test, compares with prior tests

  • Interpretation and written report generated

  • Results discussed with patient; recommendations made (follow-up testing, treatment adjustments, specialist referral if indicated)

Note

Typical Duration: 20-45 minutes per eye (depending on algorithm, patient cooperation, reliability)

KEY DISTINCTIONS - Similar CPT Codes

CodeDescriptionScopeThreshold TestingRVU (Work)Use
92084Visual field exam; extended with spherical isopters and static threshold within central 30°, or kinetic with multiple isoptersComprehensive extendedYes, full/extended0.54Glaucoma, optic nerve, neurologic VF loss
92081Visual field exam; limited (tangent screen, single stimulus level automated)Limited/screeningBasic/screening0.31Screening, blepharoplasty candidate, initial workup
92082Visual field exam; intermediate (≄2 isopters Goldmann or automated suprathreshold)IntermediateIntermediate0.42Intermediate assessment, some neurologic indications
92083Visual field exam; extended (≄3 isopters Goldmann with central 30° static, or full threshold automated programs 30-2, 24-2, 30/60-2)Comprehensive extendedYes, full/extended0.52Glaucoma monitoring, detailed assessment
92100Serial visual fields (bundled code; tracks progression over multiple tests)Multiple exams trackedDepends on component testsSpecialTrend analysis across years

Critical Distinctions:

  • 92084 vs 92083: Both are extended exams. 92084 emphasizes kinetic perimetry with multiple isopters and static central testing; 92083 emphasizes automated full threshold programs (Humphrey 30-2, 24-2, or Octopus). 92084 is often selected for kinetic (Goldmann) testing, while 92083 is more common for automated (Humphrey) testing. Some practices distinguish: if kinetic with proper isopter documentation and central 30° static = 92084; if automated full threshold = 92083.

  • 92084 vs 92082: 92084 is extended (multiple isopters, detailed central testing); 92082 is intermediate (fewer isopters, less detailed).

  • 92084 vs 92081: 92084 is comprehensive; 92081 is screening/limited (quick check, not detailed).

  • 92084 can be billed per eye (-RT/-LT) or bilateral (-50): All three codes (92081, 92082, 92083) are “unilateral or bilateral,” meaning one code covers both eyes or can specify one eye. Modifier -50 typically used for both eyes; -RT/-LT for single eye.

  • 92084 is NOT separately billable with TURBT, YAG procedures, or other intraocular procedures during the same session: Visual field testing is typically a separate diagnostic service, but bundling rules vary. Always check your MAC guidelines.

RVU BREAKDOWN - 2025

Work RVU Components

ComponentValueRepresents
Work RVU0.54Physician skill, interpretation, clinical decision-making, complexity
PE RVU (Non-Facility)0.56Perimetry equipment (Humphrey, Octopus, Goldmann), software, supplies, technician support
PE RVU (Facility)0.19Lower in facility (hospital/ASC provides equipment overhead)
Malpractice RVU0.03Malpractice insurance and liability (diagnostic test; low risk)
TOTAL (Non-Facility)1.13Sum of all components
TOTAL (Facility)0.76Lower due to reduced PE RVU

Conversion to Dollar Amount (2025 Medicare)

Formula: RVU × Conversion Factor (CF) × Geographic Practice Cost Index (GPCI) = Payment

2025 CF: $32.35

Non-Facility Calculation (GPCI = 1.0):

  • Work: 0.54 × 17.47**

  • PE: 0.56 × 18.11**

  • MP: 0.03 × 0.97**

  • Total = $36.57

Facility Calculation (GPCI = 1.0):

  • Work: 0.54 × 17.47**

  • PE: 0.19 × 6.15**

  • MP: 0.03 × 0.97**

  • Total = $24.59

Real-World Ranges (2025)

SettingRangeNotes
Non-Facility (Office)$34 - 42Varies by GPCI; typically $36 - 40
Facility (Hospital/ASC)$22 - 28Lower PE RVU; typically $24 - 26
Commercial Insurance$200 - 600+5-15× Medicare; highly payer-dependent; geographic variation
Medicaid$25 - 150State-dependent; often significantly less than Medicare
Self-Pay Cash$75 - 200Office practices charge; varies by market

2024 vs 2025 Comparison

Metric20242025Change
Work RVU0.540.54—
PE RVU (Non-Fac)0.560.56—
CF$33.29$32.35-2.83%
National Average (Non-Fac)~$37.64~$36.57-2.83%

GLOBAL PERIOD - XXX (No Global Period)

Status: XXX - No Global Period (Diagnostic Test)

What This Means:

  • 92084 has no global period (XXX code - diagnostic/assessment-only procedure)

  • No pre-operative or post-operative bundling applies

  • All services billed independently on the same day of service

  • No restrictions on billing other procedures or E/M services same day

Billing Implications:

  • Can bill 92084 + office visit (99213-99215) same day - No modifier needed on either code (standard independent billing)

  • Can bill 92084 + other diagnostic tests same day - OCT (92133, 92134), fundus photography (92250), B-scan (76514), etc.; each billed independently

  • Can bill 92084 + procedures same day - Laser (65855, 66761), intravitreal injection (67028), etc.; modify E/M with -25 if comprehensive assessment performed

  • No post-operative restrictions - Patient can be seen for other conditions immediately after VF without bundling

  • Repeat testing same day: If second VF test performed same day (rare), second test may be billed with modifier -76 (repeat by same provider) or -59 (distinct procedural service) if different clinical indication

DOCUMENTATION REQUIREMENTS - CRITICAL

Pre-Test Assessment

History - Must Document:

  • Indication for testing: Why is visual field testing medically necessary TODAY?

    • Glaucoma screening or surveillance?

    • Suspected optic nerve disease?

    • Neurologic visual loss evaluation?

    • Retinal disorder assessment?

    • Unexplained vision loss workup?

    • Blepharoplasty candidacy?

    • Post-operative baseline?

  • Ocular history:

  • Neurologic history:

  • Systemic history:

    • Diabetes? If so, type and glycemic control?

    • Hypertension?

    • Autoimmune disease?

    • Medications affecting pupil or vision?

  • Visual symptoms:

  • Family history:

    • Glaucoma in family? If so, which relatives and at what age?

    • Retinal disease, optic neuropathy, or neurologic visual disease in family?

Pre-Test Ocular Examination:

  • Visual acuity: Best-corrected visual acuity BOTH EYES (essential - poor VA affects test interpretation)

    • If patient cannot see clearly, test may be unreliable

    • If monovision (one eye corrected for distance, other for near), clarify which eye tested

  • Pupil assessment:

    • Pupil size: Dilated (mydriatic)? Naturally dilated? Undilated (miotic)?

    • Document approximate pupil size in millimeters if noted

    • Important: Dilated pupils allow better perimetry (better visibility); undilated pupils more difficult/less sensitive

  • Anterior chamber depth: Shallow? Normal? (Relevant for angle-closure glaucoma risk)

  • Intraocular pressure (IOP):

    • Current IOP (critical for glaucoma assessment)

    • Prior IOP measurements if available

    • On glaucoma medications? Which ones?

  • Optic nerve examination:

    • Cup-to-disc ratio (C/D): If glaucoma suspect, C/D critical (normal typically <0.5; glaucoma often >0.6 or asymmetric)

    • Optic nerve appearance: Normal pink, pale (atrophy), hyperemic, swollen (papilledema)?

    • Optic nerve margin: Crisp or blurred?

    • Optic nerve contour: Normal, cupped, asymmetric?

    • Spontaneous venous pulsations present? (If absent, may indicate elevated intracranial pressure)

  • Fundus examination:

    • Retinal appearance: Normal or pathologic findings?

    • Signs of glaucomatous optic neuropathy (cupping, neuroretinal rim thinning, RNFL defects)?

    • Retinal pathology (hemorrhages, exudates, degeneration)?

    • Optic disc pallor or swelling?

  • Extraocular motility (EOM):

    • Normal eye movements? Any restriction (relevant for cranial nerve lesions, restrictive optic neuropathy)?

    • proptosis (eye protrusion)? (Relevant for compression, infiltrative disease)

  • Visual fields by confrontation (informal assessment):

    • Quick gross visual field test by confrontation (show fingers in quadrants)

    • Detects major field defects; formal testing more sensitive

Test Setup Documentation - CRITICAL (Determines Test Validity):

  • Refraction for test:

    • What correction used? Contact lens or trial frame?

    • Exact refraction (sphere, cylinder, axis) - CRITICAL for comparability with prior tests

    • Importance: Different refraction can significantly alter results; must match for trend analysis

    • Document if using habitual correction vs trial frame

  • Eye tested:

    • Which eye? Right (OD) vs Left (-os) vs Both (OU)?

    • If unilateral, document why other eye not tested (cataract, media opacity, vision too poor, patient request, etc.)

  • Pupil status at time of test:

    • Dilated or undilated?

    • If dilated, pharmacologic agent used? (Tropicamide, phenylephrine, combination?)

    • Approximate pupil size in mm if possible

    • Significance: Dilated pupils improve test sensitivity and reduce artifacts

  • Test field:

    • Central 30° (most common for 92084)

    • Central 24° (often used for Humphrey)

    • Extended beyond 30° (note if done)

    • Goldmann kinetic with which isopters? (Document specific isopters tested, e.g., “I, II, III, IV”)

  • Test strategy/algorithm:

    • If automated: SITA Standard? SITA Rapid? Full Threshold? (Full Threshold more accurate but slower)

    • If Goldmann: Kinetic with which meridians? Static within central 30°?

    • Importance: Different algorithms produce different results; must match for comparison

  • Equipment used:

    • Humphrey Visual Field Analyzer (model/program)?

    • Octopus Perimeter (model/program)?

    • Goldmann kinetic perimetry?

    • Other device?

    • Importance: Different equipment may have slightly different normative databases

Intra-Test/During Procedure Documentation

Test Quality & Reliability Metrics - CRITICAL FOR INTERPRETATION:

  • Fixation losses:

    • Percentage or number reported by equipment

    • Interpretation: <20% = acceptable; 20-33% = borderline; >33% = poor reliability

    • If high fixation loss: Was patient attending to task? Significant dry eye? Neurologic issue affecting fixation?

  • False positives:

    • Patient pressed button when no stimulus presented (machine testing reliability)

    • Percentage reported by equipment

    • Interpretation: <15% = good; 15-33% = acceptable; >33% = unreliable (patient trigger-happy or not paying attention)

    • If high FP: Patient likely guessing or not understanding task

  • False negatives:

    • Patient missed high-intensity stimulus at locations known to be seeing (machine testing attention/fatigue)

    • Percentage reported by equipment

    • Interpretation: <20% = good; 20-33% = acceptable; >33% = unreliable (fatigue, inattention, or genuine neurologic loss)

    • If high FN: Patient fatigued, fell asleep, or truly has extensive field loss

  • Overall test reliability:

    • Document as “Reliable,” “Borderline,” or “Unreliable”

    • Unreliable tests require cautious interpretation; may recommend repeat when patient fresher

    • Some insurance may deny payment if test deemed unreliable; document clinical reasoning for interpreting despite poor reliability

Visual Field Results - CRITICAL:

Quantitative Data:

  • Sensitivity values/thresholds:

    • Overall pattern of thresholds across tested field

    • Areas of normal sensitivity vs depression vs absolute defects

  • Mean Deviation (MD):

    • Overall depression of visual field compared to age-matched normal

    • MD < -2 dB = suspect (field worse than normal)

    • MD < -6 dB = significant glaucomatous loss

    • More negative = more severe overall loss

    • Document specific MD value

  • Pattern Standard Deviation (PSD):

    • Measure of focal irregularities in field (not overall depression)

    • Higher PSD = more focal defects (typical of glaucoma)

    • PSD > 95th percentile suggests glaucomatous field loss

    • Document specific PSD value

  • Glaucoma Hemifield Test (GHT):

    • Proprietary algorithm detecting glaucomatous patterns

    • Categories: “Within Normal Limits,” “Borderline,” “Outside Normal Limits”

    • GHT “Outside Normal Limits” suggests glaucomatous field loss

    • Document GHT result

  • Visual Field Index (VFI):

    • Percentage of visual field remaining (0-100%)

    • Useful for tracking progression over years

    • Document VFI if available

Qualitative Description (Visual Pattern):

  • Overall pattern:

    • Normal visual field? Flat, uniform sensitivity?

    • Generalized depression? (Overall reduced sensitivity; common in media opacity, cataracts, or advanced disease)

    • Focal defect(s)? (Localized area(s) of loss)

    • If focal defects, describe location:

  • Pattern Deviation (PD) plot:

    • Describes focal deviations; helpful in detecting glaucomatous patterns

    • “arcuate defect” or “nasal step” visible on PD plot?

  • Comparison with Prior Tests (MOST IMPORTANT):

    • If prior visual fields available: Is current field stable, progressing (worsening), or improving?

    • If progressing: How much worsening? Rate of progression per year?

    • Vital for glaucoma management: Progressive field loss → treatment intensification; stable field → continue current therapy

    • Document: “Compared to [date of prior VF]: Field stable” or “Field shows progression with new [description of defect]”

  • Correlation with optic nerve:

    • Does visual field match optic nerve appearance? (Concordance = higher confidence in VF interpretation)

    • If field shows arcuate defect but optic nerve normal: May indicate early disease or may question test reliability

    • If field shows extensive loss but optic nerve relatively normal: Raises question of test reliability or non-glaucomatous cause

Interpretation & Assessment - CRITICAL:

Clinical Significance Summary:

  • Overall finding: What does this visual field show?

    • Normal? (Reassuring if glaucoma suspect; justifies continued observation)

    • Early glaucomatous loss? (Arcuate defect, nasal step, isolated point depression; indicates disease requiring treatment)

    • Moderate glaucomatous loss? (Multiple areas of defect; disease progressing; therapy likely inadequate)

    • Advanced glaucomatous loss? (Extensive loss; significant functional impairment; may affect driving, ADLs)

    • Non-glaucomatous field defect? (hemianopia, bitemporal loss, altitudinal defect; suggests non-glaucoma etiology)

  • Correlation with clinical picture:

    • Is VF consistent with clinical presentation and findings?

    • Does VF explain patient’s symptoms (if any)?

    • Any unexpected findings? (VF worse than expected from IOP/nerve or better than expected)

  • Progression status (if prior VF available):

    • Stable (same as prior) → No disease progression

    • Progressing (worsening) → Indicates inadequate IOP control or progressive disease; therapy adjustment needed

    • Improving (better than prior) → Rare; may indicate test artifact or resolution of transient process

    • Quantify if possible: “MD worsened by 2.5 dB compared to [prior date]”

  • Risk stratification:

    • Low risk: Normal or very mild glaucoma-suspect changes

    • Moderate risk: Early glaucomatous loss; requires close monitoring and treatment

    • High risk: Advanced glaucomatous loss; high risk of future vision loss if not treated aggressively

Medical Necessity Statement - CRITICAL:

  • Justify why this test was medically necessary on this date:

    • “VF performed to establish baseline in patient with newly diagnosed open-angle glaucoma and elevated IOP 26 mmHg”

    • “VF performed to monitor progression in known glaucoma patient on current therapy (latanoprost + timolol); last VF 12 months ago showed early arcuate defect”

    • “VF performed to evaluate patient with unexplained vision loss; rule out neurologic etiologies”

    • “VF performed to document visual field status before blepharoplasty surgery”

Recommendations & Follow-Up:

  • Next visual field testing:

    • When should next VF be done? (Typically 6-12 months for stable glaucoma; 3-6 months for progressive; annual for suspects)

    • Document specific recommendation: “Recommend repeat VF in 6 months for disease monitoring”

  • Interpretation and management implications:

    • Should glaucoma therapy be adjusted? (If progressing: increase drops or consider laser/surgery)

    • Should IOP target be lowered?

    • Is referral needed? (Neuro-ophthalmology for non-glaucomatous defects; glaucoma specialist if advanced loss)

    • Any other workup indicated? (Imaging: MRI if suspecting tumor; B-scan if retinal disease; carotid ultrasound if vascular event)

  • Patient education points:

    • Result explained to patient in understandable terms

    • Glaucoma implications reviewed if applicable

    • Importance of medication adherence emphasized

    • Driving safety discussed if field loss significant

Post-Test Documentation

Test Completion & Patient Status:

  • Alert and able to leave safely (non-invasive; no recovery needed)

  • Tolerating procedure well (no adverse events during testing)

  • Any difficulties: Patient unable to maintain fixation? Significant anxiety? Fatigue?

Physician Signature & Credentials:

  • Legible signature of physician or qualified non-physician practitioner

  • License/credential documentation (DEA number if applicable)

  • Date and time of interpretation

Report Storage:

  • Report generated and added to patient chart

  • Electronic or paper; legible and retrievable

  • Date of report matches or follows date of test performance

COMMON MODIFIERS

ModifierDescriptionWhen to Use
-50Bilateral ProcedureIf both eyes tested same day; some payers bundle both eyes into one payment, others allow 150% payment with -50
-RT / -LTRight / Left EyeIf only one eye tested; clarifies laterality (RT = right, LT = left); recommended for unilateral testing
-26Professional Component OnlyIf billing physician interpretation only; technician/facility performed testing and billed separately under -TC
-TCTechnical Component OnlyIf billing equipment/supplies/tech support only; physician interpretation billed separately by another provider using -26
-25Sig., Separately Identifiable E/MIf comprehensive eye exam (92002-92004, 92012-92014) performed on same day as VF; apply -25 to E/M code
-59Distinct Procedural ServiceIf two different VF tests performed same day (rare; e.g., Humphrey 24-2 AND Goldmann kinetic); use -59 on second test
-76Repeat by Same PhysicianIf same VF test repeated same day due to poor reliability or patient fatigue (uncommon)
-22Increased Procedural ServicesIf testing required substantially greater effort than typical (e.g., difficult patient, significant cooperation issues); requires documentation
-52Reduced ServicesIf VF test terminated early or partial test performed (e.g., patient unable to tolerate full test); explain in documentation
NoneStandard BillingRoutine unilateral or bilateral VF testing

Important Notes on Modifiers:

  • -50 (Bilateral): CPT code descriptor states “unilateral or bilateral,” meaning one code covers both eyes. Most MACs bundle both eyes into one payment (so don’t use -50 and don’t bill twice). Some payers allow -50 modifier for 150% payment. Check your MAC LCD for specific guidance before billing bilateral with -50.

  • -RT/-LT (Laterality): If testing ONE eye only, highly recommended to append -RT (right) or -LT (left) for clarity. Some payers require these modifiers; others don’t pay attention but it documents medical record clearly.

  • -26/-TC (Component Separation): Rarely used. 92084 typically billed globally (technician performs test, physician interprets, one fee). If split between independent practices, use -26 on physician side (interpretation) and -TC on facility side (equipment/tech). Ensure no duplicate billing.

  • -25 (E/M Same Day): If comprehensive eye exam PLUS visual field test on same day, apply -25 to the E/M code (92002-92004 or 92012-92014). Visual field test (92084) billed without modifier. Allows separate payment for both.

  • -59 (Distinct Service): Rarely needed for VF. If somehow two different VF tests performed same day (e.g., Humphrey threshold AND Goldmann kinetic for different clinical reasons), apply -59 to second test with different diagnosis code.

  • Modifiers to AVOID: Do NOT use -27 (Multiple Outpatient Hospital Procedures) unless multiple procedures in hospital on same day. Do NOT use -78 (Return to OR) or -79 (Unrelated Procedure during Postop) unless truly applicable (92084 has no global period, so these are not typically used).

MEDICARE RULES & POLICIES

1. No Global Period - Diagnostic Service

  • 92084 is XXX code (no global period)

  • No pre-operative or post-operative bundling

  • Can bill independently with other services same day without restriction

  • Repeat testing same day: Technically billable but rarely medically justified (use -76 if repeated due to poor reliability)

2. Medicare Coverage - Medical Necessity Required

  • 92084 is covered when medically necessary for diagnostic evaluation or monitoring of eye disease

  • NOT covered for: Screening asymptomatic individuals without risk factors (exception: glaucoma suspects, family history qualify)

  • Requires appropriate ICD-10 diagnosis code documenting medical necessity

3. “Interpretation and Report” Requirement - CRITICAL

  • Medicare distinguishes between “interpretation and report” vs “review of findings”

  • “Review” alone (e.g., “VF normal - no significant changes”) is NOT separately payable; bundled into E/M

  • “Interpretation and report” requires physician to:

    • Document findings (normal vs abnormal)

    • Compare to age-matched normal database (MD, PSD, GHT interpretation)

    • Assess for glaucomatous patterns or other disease

    • Correlate with prior tests (if available)

    • Document clinical significance and recommendations

    • Sign the report

  • Without proper interpretation and report, claim may be denied or downgraded to E/M inclusion

4. Frequency Limits - Payer and Indication Dependent

  • Glaucoma monitoring: Typically covered every 6-12 months for stable disease

    • High-risk or progressing glaucoma: May allow every 3-6 months

    • Very rapidly progressing: May allow up to 3× per year, but requires clinical justification

  • Glaucoma screening: Once at baseline for suspects; not repeated annually without positive findings

  • Neurologic visual loss: Frequency depends on clinical indication and stability

  • Retinal disease: Varies by disease and severity

  • Medicare may deny: Excessive testing (e.g., monthly VFs) without clinical justification; prepay review may flag for bundling if too frequent

  • Check MAC LCD: Specific frequency limits vary by jurisdiction

5. ICD-10 Diagnosis Code Linkage - CRITICAL

  • Claim MUST include appropriate ICD-10 code justifying medical necessity

  • Common approved ICD-10 codes for VF testing:

ICD-10 Code RangeConditionTypically Covered
H40.001-H40.009Unspecified open-angle glaucoma✓ Yes (most common)
H40.100-H40.139Primary angle-closure glaucoma✓ Yes
H40.201-H40.209Unspecified primary angle-closure glaucoma✓ Yes
H40.30Glaucoma secondary to eye trauma✓ Yes
H40.40Glaucoma secondary to eye inflammation✓ Yes
H40.60Glaucoma secondary to other eye disorders✓ Yes
H40.81Glaucoma with increased episcleral venous pressure✓ Yes
H40.82Hypersecretion glaucoma✓ Yes
H40.9Unspecified glaucoma✓ Yes (though less specific)
H47.011-H47.019Optic neuropathy and related conditions✓ Yes
R31.9Hematuria, unspecified? Possibly (depends on MAC/clinical context)
R42Dizziness and giddiness? Possibly (if VF workup for neurologic cause)
H53.40Scotomas in visual field✓ Yes (if documented)
H53.8Other visual disturbances✓ Yes
E10.3-E11.3Diabetes with ophthalmic complications✓ Yes (if retinal disease)
H35.10-H35.19Age-related macular degeneration✓ Yes
Z12.89Encounter for screening for other disorders? Possibly (screening context only)

Coding Rules:

  • Use most specific diagnosis code available (H40.001 better than H40.9)

  • Link diagnosis to clinical indication (don’t use “glaucoma suspect” code H40.00x0 if glaucoma confirmed)

  • If multiple conditions, use primary diagnosis linked to VF indication

  • Do NOT use: Z codes (screening codes) unless truly screening; instead use suspected or confirmed disease codes

  • Diagnosis code MUST be present on claim; missing diagnosis code = likely denial

6. Bundling with Other Services - Check MAC Guidelines

  • 92084 typically NOT bundled with office visit or other procedures

  • Can bill independently with E/M codes (apply -25 to E/M if comprehensive assessment)

  • Some MACs may bundle VF into comprehensive eye exam without modifier -25 if not separately identifiable

7. Component Separation (-26/-TC) - Rarely Used

  • 92084 usually billed globally (not split between professional and technical components)

  • If split: Ensure clear documentation of which entity performed what component

  • Avoid duplicate billing

8. Testing in Office vs Hospital vs ASC

  • Medicare pays same code regardless of setting, but PE RVU differs:

    • Office: Higher PE RVU (0.56) → Higher payment (~$36.57)

    • Hospital/ASC: Lower PE RVU (0.19) → Lower payment (~$24.59)

  • Hospital may bill separately for equipment, space, supplies

  • ASC typically includes all supplies in ASC payment

9. Bilateral Testing Billing

  • CPT code “92084” descriptor: “unilateral or bilateral”

  • Interpretation: ONE code covers both eyes OR one eye

  • Most MACs: Bundle both eyes into single payment (don’t bill twice, don’t use -50)

  • Some MACs: Allow bilateral modifier -50 for additional payment (150% of single eye rate)

  • Always verify with your MAC before billing bilateral with -50

  • If unclear: Bill as unilateral (-RT or -LT) to ensure payment, then follow up with MAC for clarification

NATIONAL & LOCAL COVERAGE

National Coverage Determination (NCD)

Status: NO specific National Coverage Determination (NCD) from CMS for CPT 92084

General Medicare Policy:

  • Visual field testing is covered under Medicare when medically necessary

  • Coverage includes diagnostic evaluation and monitoring of eye disease (glaucoma, optic nerve disease, retinal disease, neurologic visual loss)

  • “Medical necessity” requires appropriate diagnosis and clinical indication

Local Coverage Determinations (LCDs) - MAC-Specific

LCDs vary significantly by Medicare Administrative Contractor (MAC) jurisdiction.

Common Requirements Across MACs:

RequirementDetails
Medical NecessityClear clinical indication: glaucoma (diagnosed or suspect), optic neuropathy, retinal disease, neurologic visual loss, blepharoplasty candidacy, or other documented visual pathway disorder
Diagnosis CodeAppropriate ICD-10 code (H40.xx for glaucoma, H47.xx for optic neuropathy, etc.) linking VF test to medical justification
Baseline VFInitial VF for newly diagnosed glaucoma or new suspect usually covered
Monitoring VFPeriodic VF for known disease covered; typical frequency every 6-12 months for stable glaucoma
Frequency LimitsGlaucoma suspects: Typically not covered more frequently than annual; Stable glaucoma: Every 6-12 months; Progressive glaucoma: May allow every 3-6 months or up to 3× yearly with justification; Other indications: Varies
”Interpretation and Report” DocumentationPhysician must provide written interpretation addressing findings, clinical significance, and recommendations; “normal” or “no change” alone not sufficient
Comparison with Prior TestsIf prior VF available, comparison and progression assessment enhances medical necessity documentation
Correlation with Clinical FindingsVF results should correlate with optic nerve appearance, IOP, symptoms; discordance may prompt denial or request for additional documentation

Common MAC Policy Examples (Verify with Your Specific MAC):

  • Palmetto GBA (Region J): Covers VF for glaucoma diagnosis and monitoring; requires diagnosis code H40.xx; typically allows annual testing for stable glaucoma

  • National Heritage Insurance Company (NHIC - Region C): Similar coverage; may limit to 1 VF per 12 months for screening suspects; more frequent if progressive

  • Novitas Solutions (Region 5): Covers VF for glaucoma, suspects, and optic nerve disease; emphasizes “interpretation and report” requirement

  • Jurisdiction-specific policies: Each MAC may have slightly different wording of frequency limits, approved diagnoses, or documentation requirements

To Find Your MAC’s LCD:

  1. Go to: https://www.cms.gov/medicare-coverage-database/

  2. Select your MAC from dropdown

  3. Search for “visual field” or “92084”

  4. Review specific LCD requirements, diagnosis codes, frequency limits

2025 MEDICARE FEE SCHEDULE

Medicare 2025 Fee Schedule Summary

CategoryValue
Work RVU0.54
PE RVU (Non-Facility)0.56
PE RVU (Facility)0.19
Malpractice RVU0.03
Total RVU (Non-Facility)1.13
Total RVU (Facility)0.76
Conversion Factor (2025)$32.35
National Average (Non-Facility, GPCI 1.0)$36.57
Estimated Range (Non-Facility)$34 - 42
National Average (Facility, GPCI 1.0)$24.59
Estimated Range (Facility)$22 - 28

Year-over-Year Comparison (2024 vs 2025)

Metric20242025Change
Work RVU0.540.54— (no change)
PE RVU (Non-Fac)0.560.56— (no change)
CF$33.29$32.35-2.83% (decrease)
National Average (Non-Fac)~$37.64~$36.57-2.83% (decrease)

Impact: 2025 conversion factor decrease of 2.83% means ~1,284 annual revenue reduction).

Commercial Insurance & Medicaid (2025)

Payer TypeEstimated RangeNotes
Commercial Insurance$200 - 600+5-15× Medicare; highly variable by payer, product, and geography; United, Aetna, Cigna typically $250 - 400; smaller carriers may vary widely
Medicaid$25 - 150Varies dramatically by state; some states pay 100 - 150; check your state’s fee schedule
Self-Pay / Cash Price$75 - 200Office practices typically charge 75 - 100

Geographic Variation:

  • Urban practices (high GPCI): May receive 45 for Medicare
  • Rural practices (low GPCI): May receive 35 for Medicare
  • GPCI adjustment can vary 0.80-1.25 depending on location

AUDIT RED FLAGS & COMPLIANCE TIPS

Red Flags for Auditors

❌ No “interpretation and report” documented

  • Claim just says “VF normal” or “reviewed VF”

  • Missing analysis of MD, PSD, GHT, or other indices

  • No written interpretation in medical record

  • Medicare will deny or bundle into E/M

❌ No clear medical necessity stated

  • Why was this patient tested on this date?

  • No justification; claim appears elective or screening

❌ Diagnosis code doesn’t match indication

  • Code claims glaucoma (H40.xx) but documentation shows screening only

  • Diagnosis code reflects different condition than VF indication

  • Claims “hematuria workup” but codes glaucoma diagnosis

❌ Inappropriate frequency for indication

  • Monthly VF testing without documented rapid progression

  • Annual VF for newly diagnosed glaucoma (should be more frequent)

  • Multiple VFs same day without separate clinical indications

❌ Test reliability poor but not addressed

  • Fixation losses >50%, false positives >50%, false negatives >50%

  • Test marked “unreliable” but billed and interpreted anyway

  • No documentation acknowledging poor reliability or cautions about interpretation

❌ No comparison with prior tests

  • Patient has known glaucoma with prior VFs

  • Current VF not compared to prior; no progression assessment

  • Missed opportunity to document stability or progression

❌ Component billing without proper documentation

  • Billing -26 (professional) and -TC (technical) but no documentation of split

  • Single provider bills both components without explanation

  • Suggests duplicate billing

❌ Bilateral billing unclear

  • Bill 92084 × 2 or with -50 but MAC policy requires bundling

  • No documentation explaining why both eyes tested or why separate payment requested

  • Violates MAC bundling rules

❌ Equipment not documented

  • Claim submitted but no note on which equipment used (Humphrey vs Octopus vs Goldmann)

  • Algorithm/program not documented

  • Makes verification difficult for auditor

❌ Missing physician signature or credentials

  • Report generated but not signed by physician

  • “Reviewed by” but no signature

  • Medicare requires legible signature of physician or qualified NPP providing interpretation

Compliance Best Practices - Do THIS to Protect Revenue

✅ Document clear medical necessity

  • “VF performed to establish baseline in newly diagnosed POAG with IOP 24 mmHg and suspicious optic nerve cupping”
  • “VF performed to monitor progression in known glaucoma on current therapy (dorzolamide/timolol); prior VF 8 months ago showed early arcuate defect”
  • “VF performed to evaluate unexplained vision loss; rule out neurologic etiologies vs retinal disease”

✅ Write a complete interpretation and report

  • Don’t just say “normal” - explain what “normal” means
  • Document numerical results: “MD -1.5 dB, PSD 1.2 dB, GHT Within Normal Limits”
  • Describe pattern: “Flat sensitivity map consistent with normal glaucomatous profile”
  • Compare to prior: “Similar to prior VF 6 months ago; field stable”
  • Clinical significance: “No evidence of glaucomatous field loss at this time; recommend continued observation with repeat testing in 12 months”
  • Recommendations: “Continue current glaucoma therapy; repeat VF in 12 months”

✅ Document test setup precisely

  • Refraction used: “Trial frame correction: +1.00 -0.50 × 175”
  • Eye tested: “Both eyes tested (OD and -os)”
  • Pupil status: “Undilated pupils; ~3mm”
  • Equipment: “Humphrey Field Analyzer 30-2 Full Threshold”
  • Algorithm: “Full Threshold strategy”
  • This ensures test validity and comparability

✅ Address test quality/reliability

  • Fixation losses: “<15%; good fixation maintained”
  • False positives/negatives: “<20% for both; reliable test”
  • If poor reliability: “Fixation losses 30%; borderline reliability; test interpreted with caution given patient fatigue; recommend repeat when patient fresher”
  • Physician judgment preserves confidence in results

✅ Link diagnosis code to clinical indication

✅ Compare with prior tests when available

  • “Compared to VF from [prior date], field shows new arcuate defect superiorly OD, consistent with progression. MD worsened by 3.2 dB. Recommend therapy escalation.”
  • “Compared to baseline 2 years ago: Field stable; no new defects detected.”
  • Progression documentation justifies more frequent testing and therapy changes

✅ Specify modifiers when applicable

  • Unilateral testing: “92084-RT” (right eye only) or “92084-LT” (left eye only)
  • Bilateral testing: Per MAC policy—either “92084 × 2” or “92084-50” (verify your MAC)
  • Same-day E/M: Apply “-25” to E/M code (99213, etc.), not to 92084

✅ Legibly sign and date the interpretation

  • Handwritten or electronic signature acceptable; must be legible
  • Include credentials (MD, OD, PA-C, NP with ophthalmology credential)
  • Date of signature (should match or shortly follow date of test)
  • Medical malpractice insurance: Document interpreting physician’s name and credentials

✅ Check MAC LCD before submitting

  • Know your specific MAC’s frequency limits for different diagnoses
  • Know approved ICD-10 codes
  • Know documentation requirements
  • Know whether bilateral uses -50 modifier or separate billing

✅ Ensure medical record completeness

  • All documentation elements present: History, indication, setup, findings, interpretation, recommendations, signature
  • Test data (automated printout or manual plotting) attached or referenced
  • Legible and retrievable

✅ Screen for inappropriate frequency before billing

  • Patient had VF 3 weeks ago - why another one now?
  • If repeat justified (poor reliability, rapid progression), document reason
  • Medicare scrutiny increases with frequent testing; ensure medical necessity documented

FAQ - COMMON QUESTIONS

Q: What’s the difference between 92084 and 92083?
A: Both are extended visual field examinations, but emphasis differs:

  • 92083: Emphasizes automated full threshold perimetry (e.g., Humphrey 30-2, 24-2 programs; Octopus programs)
  • 92084: Emphasizes kinetic perimetry with multiple isopters (Goldmann) AND static threshold testing within central 30°
  • In practice, many use 92083 for automated (Humphrey) and 92084 for kinetic (Goldmann), though overlap exists
  • If performing Goldmann with ≄3 isopters + central 30° static testing → 92084 is appropriate
  • If performing Humphrey full threshold (30-2, 24-2) → 92083 is more common
  • Check your equipment manual and prior VF codes used by your practice for consistency

Q: What’s the difference between 92084 and 92082?
A: 92082 is intermediate; 92084 is extended.

  • 92082: ≄2 isopters on Goldmann OR automated suprathreshold; less detailed than 92084
  • 92084: ≄3 isopters on Goldmann with static central 30° testing OR automated full threshold; more comprehensive
  • 92084 codes typically reserved for comprehensive diagnostic workups and glaucoma monitoring; 92082 for screening or initial assessment

Q: Can I bill 92084 if only one eye is tested?
A: Yes. CPT descriptor states “unilateral or bilateral,” so one code covers either one eye or both eyes. If unilateral, append -RT (right) or -LT (left) to clarify which eye.

Q: Can I bill 92084 + comprehensive eye exam on the same day?
A: Yes. Apply modifier -25 to the eye exam code (92002, 92004, 92012, or 92014) to indicate “significant, separately identifiable E/M service.” Bill 92084 without modifier. Both services billed and paid independently.

Q: Is “interpretation and report” just saying “VF normal”?
A: No. Medicare requires a substantive written interpretation addressing findings, clinical significance, and comparison to norms. Simply documenting “VF normal” may be considered a “review” rather than an “interpretation and report” and may not be separately payable. Include MD, PSD, GHT or other indices; correlation with clinical findings; and recommendations.

Q: What if VF test is unreliable (high fixation loss, false positives)?
A: Document the reliability metrics and clinical judgment: “Test reliability borderline due to fixation losses of 28%; patient appeared fatigued. Results interpreted with caution pending repeat examination when patient fresher. No significant glaucomatous field loss evident despite reliability concerns.” Unreliable tests may be audited; document your clinical reasoning for interpreting results despite poor reliability.

Q: Can I bill 92084 more than once per year?
A: Depends on medical indication and MAC policy. Glaucoma suspects: Typically once per year. Stable glaucoma on therapy: Usually 6-12 months. Progressive glaucoma: May allow every 3-6 months or up to 3 times per year with clinical justification. Verify your MAC’s LCD for specific frequency limits. Claims may be denied if testing frequency deemed excessive without medical justification.

Q: If I test both eyes, do I bill 92084 once or twice?
A: Depends on MAC policy:

  • Most MACs: CPT “unilateral or bilateral” descriptor means one code covers both eyes; don’t bill twice
  • Some MACs: May allow 92084-50 (bilateral modifier) for 150% payment
  • Check your MAC LCD - policies vary by region
  • Safe approach: Bill once without modifier; if denied, appeal with documentation

Q: Can I bill 92084 + OCT (92133) on the same day?
A: Yes. Both are diagnostic tests; bill independently. No bundling between 92084 and OCT codes. Each billed with appropriate diagnosis codes.

Q: If patient has 24-2 VF today and I want to do Goldmann kinetic tomorrow, can I bill both as separate procedures?
A: Technically yes IF different clinical indications. Bill first as 92083 (automated 24-2); second as 92084 (Goldmann kinetic) with -59 modifier and separate/distinct diagnosis codes. However, clinically this is rarely necessary (one comprehensive test usually sufficient). May raise audit flags if appears to be testing fragmentation.

Q: Do I need physician signature on VF report if tech performed test?
A: Yes. Medicare requires legible physician or qualified NPP signature on the interpretation and report. Technician may perform equipment operation, but physician must review data, provide written interpretation, and sign report.

Q: What ICD-10 code should I use for “glaucoma suspect”?
A: Use H40.003 (Unspecified open-angle glaucoma, unspecified stage). NOT the “Z” screening codes unless purely screening context. If elevated IOP with risk factors: H40.003 appropriate. If confirmed glaucoma: Use more specific H40.xx code (e.g., H40.1012).

BILLING SCENARIOS & EXAMPLES

Scenario 1: Glaucoma Baseline (Office)

Patient: 58-year-old with newly diagnosed POAG

Clinical Assessment:

  • New diagnosis: Open-angle glaucoma
  • IOP OD 26 mmHg, -os 24 mmHg on no therapy
  • Optic nerve: C/D ratio OD 0.6, OS 0.5 (asymmetric; OD suspicious)
  • Prior VF: None

Indication: Establish baseline visual field to document any glaucomatous loss before starting therapy

Procedure:

  • Humphrey 30-2 Full Threshold automated perimetry, OD and OS
  • Pupil undilated; refraction correction applied
  • Fixation losses 12%, false positives 8%, false negatives 6% (all acceptable; reliable test)
  • Results OD: MD -1.8 dB, PSD 1.5 dB, GHT Borderline
  • Results OS: MD -0.5 dB, PSD 1.0 dB, GHT Within Normal Limits

Interpretation:
“Comprehensive automated visual field testing reveals mildly depressed sensitivity OD (MD -1.8 dB) with borderline GHT, suggesting possible early glaucomatous damage. OS relatively normal (MD -0.5 dB). Results correlate with asymmetric optic nerve cupping noted on clinical exam. Baseline for monitoring with glaucoma therapy initiation. Recommend repeat VF in 6 months to assess response to treatment.”

Coding:

  • 92084 (or 92083 if using 30-2; verify your practice convention)
  • ICD-10: H40.003 (Open-angle glaucoma, unspecified stage)
  • Medicare Payment: ~$36.57 (office, non-facility)
  • Notes: If bilateral testing, some practices bill 92084 × 2; check your MAC

Scenario 2: Glaucoma Progression (Office)

Patient: 72-year-old with known POAG on therapy

Clinical Assessment:

  • Prior VF: 8 months ago; MD -2.3 dB OD, -1.5 dB OS; no significant changes from 2 years prior
  • Current VF indication: Routine monitoring; on dorzolamide + timolol OD, on latanoprost OS
  • Current IOP: OD 20 mmHg, OS 18 mmHg (on therapy)
  • Optic nerve exam: Stable from prior

Procedure:

  • Humphrey 30-2 Full Threshold, both eyes
  • Test reliable (fixation losses 10%, false positives 5%, false negatives 8%)
  • Results OD: MD -4.1 dB (worsened from -2.3), PSD 2.8 dB (increased from 1.5), GHT Outside Normal Limits
  • Results OS: MD -1.8 dB (stable from -1.5), PSD 1.2 dB (stable), GHT Borderline

Interpretation:
“Repeat automated visual field testing shows significant progression OD with MD worsening by 1.8 dB compared to examination 8 months ago. New arcuate defect superiorly noted on pattern deviation plot, consistent with glaucomatous progression despite IOP lowering on dorzolamide/timolol. OS field relatively stable. Progressive glaucomatous damage OD indicates inadequate IOP control on current therapy. Recommend glaucoma specialist evaluation for therapy intensification (addition of third agent or consideration of laser/surgical intervention). Close monitoring indicated; repeat VF in 3 months.”

Coding:

  • 92084
  • ICD-10: H40.1012 (Primary open-angle glaucoma, right eye, moderate stage; reflects progression)
  • Medicare Payment: ~$36.57
  • Clinical Significance: Documented progression justifies more frequent VF (3-month interval) and therapy escalation

Scenario 3: Neurologic Visual Loss Evaluation

Patient: 64-year-old with sudden vision loss and headaches

Clinical Assessment:

  • Chief complaint: Sudden dimming of vision OS × 3 days, headaches
  • Concerned for stroke or other neurologic event
  • Exam findings: Visual fields by confrontation show left homonymous hemianopia (loss of left half vision both eyes)
  • Imaging: MRI pending; neurology consulted
  • VF today: To document visual field deficit objectively and help localize lesion

Procedure:

  • Humphrey 30-2 Full Threshold perimetry
  • Results: Left homonymous hemianopia (loss of left half visual field in both OD and OS)
  • Pattern consistent with right-sided brain lesion (optic tract, optic radiations, or occipital cortex)

Interpretation:
“Automated visual field testing confirms left homonymous hemianopia, with loss of entire left half visual field in both eyes. Pattern consistent with right-sided lesion affecting optic pathway (optic tract, Meyer’s loop, or occipital cortex) rather than ocular pathology. Findings support concern for acute neurologic event (possible stroke). Recommend urgent neurology evaluation and imaging (MRI brain with contrast) to localize lesion and determine etiology. Ophthalmology baseline established for future comparison.”

Coding:

  • 92084 (or 92083; used for extended evaluation of neurologic visual loss)
  • ICD-10: R53.1 (Weakness, left side) or H53.40 (Scotoma in visual field) or pending specific neurologic diagnosis
  • Medicare Payment: ~$36.57
  • Notes: This case demonstrates non-glaucomatous use of comprehensive VF testing; appropriate for workup of acute vision loss

REFERENCES & RESOURCES

  • CMS Medicare Physician Fee Schedule (MPFS) 2025 Final Rule - CMS.gov
  • Medicare Claims Processing Manual (MCPM) Chapter 13 - “Interpretation of Diagnostic Tests”
  • CPTÂź Professional Edition 2025 - American Medical Association
  • ICD-10-CM Official Guidelines for Coding and Reporting - CMS.gov
  • Virtual Field Blog: “Medicare Visual Field Testing 2025: CPT Codes & Coverage” - virtualfield.io
  • AAPC Optometry Coding & Billing Alert: “Visual Fields - Get Answers to Your VF Questions”
  • Glaucoma Today Magazine: “Reimbursement for Repeat Visual Field Testing” & glaucomaphysician.net
  • Individual MAC Local Coverage Determinations (LCDs) - https://www.cms.gov/medicare-coverage-database/

Document Status: Complete & Ready for Obsidian Vault
Last Updated: February 2026
Next Update Due: December 2026 (2027 Fee Schedule Release)

Graph View

Recent Notes